### PROGRESS REPORT

December 1, through December 31, 1996

#### OFFICE OF NAVAL RESEARCH GRANT NO:

N00014-95-1-0055

19970505 151

Approved for public releases:

Distribution Unitenited

National Marrow Donor Program® 3433 Broadway Street N.E.
Suite 500
Minneapolis, MN 55413

March 5, 1997

#### TABLE OF CONTENTS

| I. | PROJECT DESCRIPTION1   |  |
|----|--|--|
|    | A. Specific Aims   |  |
|    | B. Budgeted Categories   |  |
|    | 4. \$24,000 Histocompatibility Laboratories for HLA-A, B & DR Typing   |  |
|    | 6. \$553,625 Repository       1         7. \$600,000 Feasibility for Confirmatory Class I DNA Testing       1  |  |
|    | 8. \$0 Contract Laboratory for Reference/Pre-Test Cells (Reallocated)  |  |
|    | 10. 915,671 Donor Center Hardware/Software2  |  |
|    | 11. \$500,000 Facilitation of Rapid Communication with Foreign Registries212. \$12,717 Probability of A, B, DR Identical Matches213. \$200,000 Revision of Search Algorithm2 |  |
|    | 14. \$211,326 Data Management for the International Consortium on the Effects of Radiation/Studies of effects of Exposure to Ionizing Radiation                              |  |
|    | 15. \$34.680 HR/HW Search  |  |
|    | 16. \$0 Resolution of Discrepant HLA Typing on Donors (Realllocated)   |  |
|    | 18. \$0 Enhancements to BMDW Processing (Reallocated)  |  |
|    | 19. \$0 Cord Blood Repository Software (Reallocated)   |  |
|    | 20. \$0 Transplant Center Software (Reallocated)221. \$0 Modify Repository Software (Reallocated)2   |  |
|    | 22. \$11,425,000 Minority HLA-A, B Typing  |  |
|    | 23. 67,833 National Minority Campaigns2  |  |
|    | 24. \$300,000 Pilot Recruitment/Retention Program  |  |
|    | 25. \$6,250,406 Community HLA-A, B Matching Funds       2         26. \$5,859 Donor Center Waiting Lists       2   |  |
|    | 27. \$135,000 Physician Histocompatibility and Transplant Center Coordinator Education2  |  |
|    | 28. \$972,291 Registry Wide Newsletter   |  |
|    | 29. \$0 Transplant and Collection Center Newsletter (Reallocated)  |  |
|    | 30. \$3,898 Physician Education  |  |
|    | 31. \$16,358 Patient Education   |  |
|    | 32. \$0 NMDP Speaker Support Materials (Reallocated)   |  |
|    | 33. \$479,599 Targeted Group Awareness and Education Activities  |  |
|    | 34. \$549,854 Integrated Communications for Targeted Campaigns3  |  |
|    | 35. \$0 Phase II National Public Service Campaign (Reallocated)  |  |

|          | \$256,989 Long Term Blood Storage Alternative Investigations                  |   |
|----------|---|---|
|          | \$615,297 Program Administration\$266,799 Alternative Blood Products Software |   |
| 38.      | \$200,799 Alternative Blood Products Software                                 |   |
| II. RESU | LTS BY CATEGORY   | 3 |
| A. HL    | A Typing And Research   | 3 |
|          | cientific Studies of Allele-Specific Typing of Donor\Recipient Samples        |   |
| 3. H     | listocompatibility Laboratories for DNA HLA-DR Typing                         | 4 |
|          | epository   |   |
| 7. F     | easibility for Confirmatory Class I DNA Testing                               | 5 |
| B. Elec  | etronic Communication   | 5 |
| 1. D     | Oonor Center Hardware/Software  | 5 |
|          | acilitation of Rapid Communication with Foreign Registries                    |   |
|          | evision of Search Algorithm   |   |
|          | Cord Blood Repository Software  |   |
| C. Dot   | nor Services Activities   | 6 |
|          | ilot Recruitment/Retention Programs   |   |
| D D 1    |   | _ |
|          | blic education and Awareness  |   |
|          | hysician Education  |   |
|          | ntegrated Communications for Targeted Campaigns                               |   |
| 0. II    | Regrated Communications for Targeted Campaigns                                |   |
| E. Lon   | ng Term Blood Storage Alternative Investigations                              | 9 |
| F. Pro   | gram Administration   | 9 |
| III. SUM | MARY  | 9 |
|          | ACHMENTS  |   |
| IV. AII. | ACHMENTS  |   |
| 1.       | Reallocation Report   |   |
| 2.       | High Resolution Class I DNA Typing Laboratories                               |   |
| 3.       | A. Donor Typings Performed  |   |
|          | B. Donor Samples Stored and Shipped   |   |
| 4.       | 1996 ASH Symposium Registration Summary                                       |   |
| 5        | ASH Symposium Evaluation  |   |
| 5.       | ASH Symposium Evaluation  |   |

#### PROGRESS REPORT FOR OFFICE OF NAVAL RESEARCH

GRANT NO: N00014-95-1-0055

(As Modified through P00001, A00002)

This periodic progress report covers activities supported by Grant #N00014-95-1-0055, as modified, from December 1, through December 31, 1996. This Grant was due to expire on September 30, 1996. Amendment A00002 extended it through December 31, 1996. Amendment A00003 extended it through September 30, 1997. As only 12 budgeted line items will have activity, this report will be limited to those items in this report and in the future.

#### I. PROJECT DESCRIPTION

#### A. Specific Aims

During this period, the National Marrow Donor Program® (NMDP) used grant funds to support activities directed toward the following goals.

- 1. Enhance an already effective system which rapidly identifies and tracks the availability of matched donors for patients requiring marrow transplants.
- 2. Increase the total number and racial diversity of NMDP's volunteer donor file and provide HLA-DR typing on as many donors as possible in an effort to reduce patient search time and costs.
- 3. Perform HLA typing of the donor/recipient samples stored in NMDP's research sample repository, and compare the detailed molecular typing results with patient outcome data to determine the correlation between post-transplant outcome and degree of HLA match.

#### B. Budgeted Categoriesa

- 1. \$4,550,000 Scientific Studies of Allele-Specific Typing of Donor\Recipient Samples.
- 2. \$0 NMDP HLA Match Vs. Outcome Research (Reallocated)
- 3. \$16,477,798 Histocompatibility Laboratories for DNA HLA-DR Typing
- 4. \$24,000 Histocompatibility Laboratories for HLA-A, B & DR Typing
- 5. \$0 NMDP Staff Immunogeneticist (Reallocated)
- 6. \$553,625 Repository
- 7. \$600,000 Feasibility for Confirmatory Class I DNA Testing

- 8. \$0 Contract Laboratory for Reference/Pre-Test Cells (Reallocated)
- 9. \$100,000 Class I Sequencing Database
- 10. \$915,671 Donor Center Hardware/Software
- 11. \$500,000 Facilitation of Rapid Communication with Foreign Registries
- 12. \$12,717 Probability of A, B, DR Identical Matches
- 13. \$200,000 Revision of Search Algorithm
- 14. \$211,326 Data Management for the International Consortium on the Effects of Radiation/Studies of effects of Exposure to Ionizing Radiation
- 15. \$34,680 HR/HW Search
- 16. \$0 Resolution of Discrepant HLA Typing on Donors (Reallocated)
- 17. \$75,000 Donor HLA Override Modifications
- 18. \$0 Enhancements to BMDW Processing (Reallocated)
- 19. \$0 Cord Blood Repository Software (Reallocated)
- 20. \$0 Transplant Center Software (Reallocated)
- 21. \$0 Modify Repository Software (Reallocated)
- 22. \$11,425,000 Minority HLA-A, B Typing
- 23. \$67,833 National Minority Campaigns
- 24. \$300,000 Pilot Recruitment/Retention Program
- 25. \$6,250,406 Community HLA-A, B Matching Funds
- 26. \$5,859 Donor Center Waiting Lists
- 27. \$135,000 Physician Histocompatibility and Transplant Center Coordinator Education
- 28. \$972,291 Registry Wide Newsletter

- 29. \$0 Transplant and Collection Center Newsletter (Reallocated)
- 30. \$3,898 Physician Education
- 31. \$16,358 Patient Education
- 32. \$0 NMDP Speaker Support Materials (Reallocated)
- 33. \$479,599 Targeted Group Awareness and Education Activities
- 34. \$549,854 Integrated Communications for Targeted Campaigns
- 35. \$0 Phase II National Public Service Campaign (Reallocated)
- 36. \$256,989 Long Term Blood Storage Alternative Investigations
- 37. \$615,297 Program Administration
- 38. \$266,799 Alternative Blood Products Software

#### II. RESULTS BY CATEGORY

#### A. HLA Typing And Research

1. Scientific Studies of Allele-Specific Typing of Donor\Recipient Samples

This project's primary objective is to determine the impact of HLA matching, defined by the highest resolution of molecular typing possible, on transplant outcome. The project was initiated with funding from Navy Grant N00014-93-1-0658 and continues under funding from this grant. There are three phases to this study. Phase I continues the allele level class II typing on the donor-recipient samples stored in the NMDP's repository at Irwin Memorial Blood Center; Phase II entails obtaining allele-level class I typing on the donor-recipient samples; and Phase III involves data analysis and transplant outcome correlation.

#### Phase I

The nine laboratories involved in this phase of the project have now completed the typings of the first 1302 donor-recipient pairs funded under Navy grant N00014-93-1-0658. The level of resolution for continuation of this phase has been defined upon evaluation of competitive bids, 6 laboratories were selected to continue participation in this project. The new contracts and typing of 1,000 new donor recipient

paired samples began in December 1996. We will begin to receive results in January 1997.

#### Phase II

Samples were forwarded to participating contract laboratories during the months of November and December 1995. Typing of these samples is currently in progress, and is expected to be completed by February-March. Results reported to date are detailed in Attachment 2. Quotes from participating laboratories for continued typing of an additional 1,500 pairs were solicited and were due December 16, 1996.

The NMDP will be responsible for the management of the data generated by the class I and II typing laboratories. Software and programming to manage the data and to make the necessary comparison was completed January 1996.

#### 3. Histocompatibility Laboratories for DNA HLA-DR Typing

In February 1992, a DNA pilot project was implemented to test the feasibility of using DNA technology, specifically Polymerase Chain Reaction (PCR) Sequence Specific Oligonucleotide Probe (SSOP) typing to identify the class II antigens at the HLA-DR and DQ loci. An additional focus of the pilot project was to institute a quality control system which would monitor the performance of the laboratories and establish an accuracy standard for PCR-SSOP typing. The pilot project successfully demonstrated that prospective collection of HLA-DR samples for storage and later typing by DNA contract laboratories was an efficient option for prospective HLA-DR typing of large numbers of volunteer donors as well as for patient-directed typing. In addition, the blind quality control program has shown that molecular HLA-DR typing can be performed at high volume and low cost and still be highly accurate (less than a 2% error rate overall). The efforts of the pilot project were funded under Navy grant N00014-91-J-1895.

Based on the success of the DNA pilot project, the program was expanded (under funding provided through Navy grants N00014-92-J-1551 and N00014-93-1-0658) to include two DNA repositories, 16 contract DNA typing laboratories and all NMDP donor centers. The design of the DNA project remained virtually identical to that of the pilot project and continues to include ongoing quality control. Funding for these typings was provided through this Navy grant beginning on March 1, 1995. Prior to that time, Navy Grant N00014-93-1-0658 funded the typings for this project. Attachment 3A details the activities of these laboratories. During this reporting period the typing activities were funded through a contract between the NMDP and the Health Resources and Services Administration (HRSA).

#### 6. Repository

The NMDP's two DNA repositories (American Red Cross National Headquarters and Children's Hospital of Pittsburgh) continued to receive samples from virtually all of the NMDP's donor centers. Approximately 90%-95% of all newly recruited donors have samples submitted to one of the two NMDP DNA repositories. Currently, repository services provided by the Children's Hospital of Pittsburgh are funded separately. The activity of the two repositories during the report period is detailed in Attachment 3B.

#### 7. Feasibility for Confirmatory Class I DNA Testing

The technology of molecular HLA typing for identification of class I HLA types has progressed rapidly in the past few years. Although the technology is not as advanced as in class II HLA typing, it has progressed to the point where antigen-level typing can be performed by molecular means for the HLA-A and B loci.

The feasibility of developing a network of labs to perform DNA-based HLA-A, B typing, the impact on existing procedures and practices at the transplant centers and DNA repositories, and the costs associated with developing this network would be determined and used to evaluate whether network-wide implementation is possible. utilizing molecular class I typing lies in the ability to perform a very accurate, detailed molecular typing on a stored sample, to confirm a questionable result or to implement confirmatory typing while the donor is completing other parts of the search process, such as the information session or physical exam. Either scenario would result in a shortened search process, because fewer discrepant samples would be identified in later stages of the search process. The ability to conduct confirmatory typing in parallel with other donor procedures would significantly shorten the search process, saving lives in those cases when the patient has little time to spare. An RFP was released November 1, 1996, to solicit proposals from laboratories capable of performing DNA-based HLA-A, B typing. Proposals from 35 laboratories were received by the December 13 due date. The technical review of these proposals will be held February 20, 1997. Since the RFP was just released, no funds have been expended in this category to date.

#### **B.** Electronic Communication

#### 1. Donor Center Hardware/Software

The conversion of STAR Link<sup>TM</sup> to all domestic donor centers using DMAT has been completed. As of the end of November 1996, 78 donor centers were successfully converted to STAR Link.

#### 2. Facilitation of Rapid Communication with Foreign Registries

The NMDP is working in cooperation with foreign registries to provide international data exchange and to streamline international searches. The STAR® system has been installed and is currently operating at the Australian Bone Marrow Donor Registry (ABMDR) in Australia. As of December 1996, requirements have been defined for an upgrade of ABMDR's version of the STAR application. A duplicate of ABMDR's system has been set up at the NMDP to provide a test environment for the upgrade. As of December 1996, testing has begun on the new STAR release to the Australian Registry.

NMDP preliminary searches are sent electronically on a daily basis to the Anthony Nolan Bone Marrow Trust in England, who then returns a file of search results. A similar interface has been designed, developed and tested for France Greffe de Moelle (FGM). The NMDP began electronically sending preliminary searches to the FGM in July of 1996.

#### 4. Revision of Search Algorithm

Although the STAR system stores the DNA typing data for both donors and recipients, the current matching algorithm evaluates the match grade based upon serologic equivalent typing results. The NMDP Histocompatibilty Committee addressed the need to revise the algorithm to incorporate molecular-based matching at its November 6, 1995, meeting. A working group of histocompatibilty experts and transplant center physicians has been assigned to define the matching criteria. All the funding available for this project in N00014-95-1-0055 has been expended, however, effort continues under the Cooperative Agreement.

#### 10. Cord Blood Repository Software

This category has been reallocated to \$0. Effort on this project has been delayed due to completion of other cord blood phases. These funds were reallocated in March 1996 to fund the Alternative Blood Products Software.

#### C. Donor Services Activities

#### 3. Pilot Recruitment/Retention Programs

In 1993, the NMDP requested Navy funds to continue minority focused recruitment efforts after the targeted campaigns were completed. The goal was to develop models for each racial/ethnic group that would maximize the numbers of donors recruited onto the registry and also improve retention of these donors when they were contacted for further testing on behalf of a patient.

The NMDP seeks to build on previous programs funded by the Navy with special attention to those recruitment strategies and programs that

have proven to be most successful and appear to provide the greatest opportunity for replication in other areas.

A Request for Proposal (RFP) was let in the spring of 1995 to community based organizations and donor centers in selected geographic areas. The response was very low and determined not to be competitive. The Navy was asked to allow NMDP to redefine the use of the funds for this program for the following:

- Provide an opportunity for existing NMDP recruitment groups (8) that focus on minority recruitment to receive one recruitment staff position. The RFP was let in June 1996 with a response deadline of July 19, 1996. Four (4) recruitment groups were awarded subcontracts for a Coordinator for Minority Public Education/Awareness, based on proposals submitted and reviewed through June 1997.
- Provide staff support for the American Indian/Alaska Native initiative, especially for health professional education about unrelated marrow transplantation.

Remaining funds were reallocated out of this line item for community matching typings.

#### D. Public education and Awareness

#### 4. Physician Education

NMDP presented a Symposium at the American Society of Hematology (ASH) annual meeting in Orlando, Florida on December 6, 1996. NMDP's was one of 21 selected by ASH. The Symposium "Donor Options and Stem Cell Choices: Transplant Considerations for the Patient without an HLA-identical Sibling" featured presentations from six researches and clinicians who addressed hematopoietic stem cell transplantation. They highlighted the outcomes of unrelated donor transplants, mismatched family transplants, cord blood transplants, and autologous transplants. The role if the minor histocompatibility antigens in transplantation as well as methods to overcome HLA disparity were also discussed.

An audience of approximately 500 physicians and scientists attended the Symposium and provided an overall rating of either good or excellent (see enclosed summary of evaluations and attendee statistics).

This meeting is an excellent forum for the NMDP, as it draws over 12,000 attendees worldwide. NMDP plans to submit an application to ASH in February for the 1997 Symposium selection.

#### 7. Targeted Group Awareness and Education Activities

C&E staff continues to create new opportunities to generate visibility in the media and help our local centers increase the potential success of events and activities designed to raise awareness of the need for volunteers, particularly minorities, to join the Registry.

Media coverage during December included: Geraldo, Inside Edition, Hard Copy and continued exposure on Univision, a Spanish language channel.

December was a strong month for public awareness, particularly among minority callers. Of the 13,929 calls to the 800 number during December, 32 percent were from minority callers, with 21 percent of the minority callers being Hispanic.

Staff also develops and distributes newsletters with media relations and recruitment tips specific to the targeted populations. This month newsletters for the Hispanic and Asian activities were distributed to network staff through the week mailing. Periodically, network staff contribute articles about their success stories and examples of what worked in their communities.

#### 8. Integrated Communications for Targeted Campaigns

NMDP uses communications firms with cultural experience and resources specific to each targeted audience. The expertise of C&E and the firms enables development of culturally sensitive, campaign-specific materials in languages key to our audiences. These materials are tested among representative groups for cultural sensitivity and effectiveness. Additionally, the firms provide a resource with non-English speaking minority media.

Staff is working closely with the campaign markets and our hired communications firm Valencia Perez and Echeveste (VPE) to develop a plan for a series of media breakfasts. The events will serve as a vehicle for widespread distribution of the public service announcements and will be specifically designed to attract public service directors, as opposed to reporters. This will help our coordinators develop relationships with an important segment of the media audience they are not as familiar approaching and will help foster relationships that can lead to more consistent placement of PSAs in the future.

Work continues with Red Eagle Productions on the remaining materials for the American Indian/Alaska Native Initiative. This includes development of radio and television public service announcements, stationery, and a folder.

#### E. Long Term Blood Storage Alternative Investigations

A contract (#6030) with Coriell Institute for Medical Research was issued on March 1, 1995, to evaluate alternative methodologies of long term whole blood storage and to compare them with the current protocol of freezing whole blood in 1 ml aliquots. Based on less than satisfactory performance, this contract was terminated for convenience of the NMDP on November 7, 1995. An amount of \$6,989 was made to Coriell as complete payment for services performed. It is anticipated that the remaining funds will be utilized to fund a new study for alternative methods of long term whole blood storage.

#### F. Program Administration

During this period no funds were expended from this category to cover the salary, office rental, and related expenses of the Administrator, Navy Funded Programs. Attachment 1 contains a reallocation recapitulation schedule through the end of December 1996. This schedule reflects all approved reallocations.

Grant Modification A00003 was received, which extended the period of performance of the Grant to 30 September 1997, and incorporated the revised budget (reallocation request #9).

#### III. SUMMARY

Navy grant # N00014-95-1-0055 continues to support NMDP projects which decrease the time and expense required for patients to find compatible unrelated donors, while funding research designed to increase understanding of the role of HLA matching on patient outcome post-transplant. Many of the activities described in this report represent continuations of successful projects implemented previously.

\$45,000,000 NAVY GRANT SUMMARY OF ACTIVITIES

# HIGH RESOLUTION CLASS I DNA TYPING LABORATORIES

# CUMULATIVE DISTRIBUTION OF TYPING RESULTS BY LOCUS TOTAL FOR ALL LABS December 31, 1996

|      |     |           |              |        | RESULTS       | ILTS |             |        |            |       |
|------|-----|-----------|--------------|--------|---------------|------|-------------|--------|------------|-------|
| RE   | SU  | RESULTS   |              |        | <b>PARTLY</b> | ILY  | RESULTS NOT | LS NOT | RESULTS NO | LS NO |
| CON  | IPL | COMPLETED | RESULTS OPEN | S OPEN | COMPLETED     | ETED | COMPLETED   | ETED   | MAKE       | KE    |
| #    |     | %         | #            | %      | #             | %    | #           | %      | #          | %     |
| 1906 | 9   | 63.5      | 727          | 24.2   | 346           | 11.5 | 1073        | 35.7   | 24         | 0.8   |
| 1619 | 6   | 54.0      | 1143         | 38.1   | 238           | 7.9  | 1381        | 46.0   | 0          | 0.0   |
| 2036 | 9   | 6.79      | 839          | 28.0   | 125           | 4.2  | 964         | 32.1   | 0          | 0.0   |
| 5561 | -19 | 61.8      | 2709         | 30.1   | 402           | 7.9  | 3418        | 38.0   | 24         | 0.3   |

= # of IDs that will be typed at a given locus RQSTD = # of IDs where 2 valid results have been received

COMPLETED

= # of IDs where no results have been received OPEN = # of IDs where 1 valid result has been received but the second result has not been received PARTLY COMPLETED

= Sum of OPEN and PARTLY COMPLETE NOT COMPLETED

NO MAKE

= # of IDs where a no make has been received at one or both alleles

(A) DONOR TYPINGS PERFORMED
(B) DONORS SAMPLES STORED AND SHIPPED

# NAVY GRANT N00014-95-1-0055 REALLOCATIONS REPORT

Reallocation \*

| Scientific Studies of Alber-Specific Typing of Deard R  | (\$34,680) (\$100,000) (\$120,000) (\$172,328) (\$100,000) (\$130,000) (  | (\$500,000)<br>(\$500,000)<br>\$2,477,798<br>(\$1303,642)<br>\$750,000 (\$800,000)<br>(\$1,084,329)<br>(\$1,88,674)<br>(\$1,88,674) | Grant Amount 54,550,000 516,477,798 524,000 524,000 5915,671 5500,000 5915,671 5500,000 5210,  |
|---|---|---|---|
| Budget   P00001   GRANT AMOUNT   0214495   0600695   07   07   07   07   07   07   07   0   | (\$100,000)  \$2,000,000  \$2,000,000  \$2,000,000  \$2,000,000  \$34,680  \$34,680  \$34,680  \$34,680  \$3100,000)  \$3100,000)  \$3100,000  \$3100,000)  \$3100,000)  \$3100,000)  \$3100,000)  \$310,000)  \$310,000)  \$310,000)  \$310,000)   |   | Autount 54,550,000 516,477,798 524,000 524,000 50,000 511,000 511,306   |
| A   | \$2,000,000<br>\$2,000,000<br>\$172,358)<br>\$300,000<br>\$300,000<br>\$34,680<br>\$34,680<br>\$150,000)<br>\$1150,000<br>\$1100,000)<br>\$11,275,000<br>\$11,275,000<br>\$100,000)   |   | \$4,550,000<br>\$16,477,798<br>\$16,477,798<br>\$253,602<br>\$100,000<br>\$12,717<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$216,671<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,000<br>\$200,             |
| LA DR Typ   | \$2,000,000<br>(\$2,300,000)<br>(\$2,300,000)<br>\$300,000<br>\$34,680<br>\$34,680<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)<br>(\$100,000)   |   | \$0<br>\$24,000<br>\$24,000<br>\$253,625<br>\$660,000<br>\$915,671<br>\$250,000<br>\$915,671<br>\$250,000<br>\$211,326<br>\$250,000<br>\$211,326<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$250,000<br>\$2     |
| LA DR Typ         \$6,700,000         \$1,300,000         \$12,000,000           B & DR T         \$2,300,000         \$2,300,000         \$2,300,000         \$34,680)           Cells         \$100,000         \$100,000         \$100,000         \$100,000         \$100,000           Cells         \$0         \$100,000   | \$34,680 (\$172,358) (\$1 |   | \$16,477,798<br>\$24,000<br>\$253,625<br>\$600,000<br>\$100,000<br>\$115,671<br>\$200,000<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$210,700<br>\$         |
| B & DR T         \$2,300,000         \$2,800,000         \$2,800,000         \$34,680)           Testing         \$0         \$100,000         \$100,000         \$300,000         \$340,000         \$340,680)           1 Cells         \$0         \$100,000         \$100,000         \$100,000         \$300,000         \$340,000   | (\$34,680)     (\$283,000)     (\$100,000)       \$34,680     (\$100,000)     (\$100,000)       (\$100,000)     (\$100,000)     (\$12,235)  |   | \$24,000<br>\$553,625<br>\$600,000<br>\$1100,000<br>\$12,717<br>\$200,000<br>\$211,326<br>\$211,326<br>\$75,000<br>\$75,000<br>\$75,000<br>\$75,000<br>\$75,000<br>\$000,000  |
| \$200,000         \$200,000         \$400,000         \$34,680)           resting         \$0         \$700,000         \$700,000         \$34,680           Cells         \$0         \$100,000         \$100,000         \$34,680           Cells         \$0         \$1,000,000         \$100,000         \$100,000           Overign Regi         \$50,000         \$1,000,000         \$100,000         \$100,000           sortium on t         \$250,000         \$150,000         \$150,000         \$134,680           sortium on t         \$250,000         \$150,000         \$150,000         \$134,680           bonors         \$0         \$175,000         \$150,000         \$134,680           bonors         \$0         \$150,000         \$150,000         \$134,680           bonors         \$0         \$175,000         \$175,000         \$175,000           \$0         \$175,000         \$175,000         \$175,000         \$175,000           \$0         \$175,000         \$175,000         \$175,000         \$175,000           \$0         \$175,000         \$175,000         \$175,000         \$175,000         \$175,000           \$1         \$250,000         \$175,000         \$175,000         \$175,000         \$175,000  | (\$34,680) (\$283,000)  \$300,000  \$34,680  (\$100,000)  (\$150,000)  (\$150,000)  |   | \$0<br>\$553,625<br>\$600,000<br>\$100,000<br>\$12,717<br>\$200,000<br>\$211,326<br>\$34,680<br>\$75,000<br>\$75,000<br>\$0<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$100,000<br>\$ |
| Fishing \$10 (596,375)  Festing \$10,000 (596,375)  Festing \$10,000 (50,000 (596,375)  Fig. \$100,000 (50  | \$34,680<br>(\$100,000)<br>(\$150,000)<br>(\$150,000)   |   | \$553,625<br>\$600,000<br>\$100,000<br>\$915,671<br>\$12,717<br>\$200,000<br>\$211,326<br>\$24,680<br>\$75,000<br>\$50<br>\$50<br>\$50<br>\$50<br>\$50<br>\$50<br>\$50<br>\$50<br>\$50  |
| Celis   | \$300,000<br>(\$100,000)<br>(\$150,000)<br>(\$100,000)  | (\$1,084,329)<br>(\$37,283)<br>(\$188,674)<br>(\$75,000)  | \$600,000<br>\$100,000<br>\$915,671<br>\$12,717<br>\$200,000<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211,326<br>\$211         |
| 1 Cells         \$100,000         \$100,000           1 Cells         \$100,000         \$100,000           \$1,000,000         \$1,000,000         \$2,000,000           Oreign Regi         \$500,000         \$0         \$50,000           \$200,000         \$0         \$50,000         \$0           \$200,000         \$0         \$50,000         \$0           \$200,000         \$0         \$50,000         \$0           \$200,000         \$0         \$50,000         \$0           \$200,000         \$150,000         \$400,000         \$34,680           \$0         \$75,000         \$400,000         \$34,680           \$0         \$75,000         \$400,000         \$100,000           \$0         \$150,000         \$100,000         \$100,000           \$0         \$150,000         \$110,000         \$110,000           \$0         \$150,000         \$11,500         \$100,000           \$0         \$100,000         \$11,500         \$100,000           \$0         \$100,000         \$11,500         \$100,000           \$1,000,000         \$100,000         \$10,000         \$10,000           \$21,000,000         \$21,000,000         \$10,000         \$10,000      <  | (\$100,000)<br>(\$150,000)<br>(\$100,000)   | (\$1,084,329)<br>(\$37,283)<br>(\$188,674)<br>(\$75,000)  | \$0<br>\$100,000<br>\$915,671<br>\$12,717<br>\$200,000<br>\$211,326<br>\$34,680<br>\$75,000<br>\$0<br>\$75,000  |
| \$0         \$100,000         \$1,000,000           Serion (continuo on table)         \$1,000,000         \$2,000,000           Sortium on table)         \$500,000         \$0         \$500,000           \$0         \$150,000         \$400,000         \$150,000           \$0         \$150,000         \$100,000         \$100,000           \$0         \$100,000         \$100,000         \$100,000           \$0         \$100,000         \$100,000         \$100,000           \$1,000,000         \$2,150,000         \$11,000,000         \$100,000           \$220,000         \$100,000         \$11,000,000         \$100,000           \$21,000,000         \$100,000         \$100,000         \$100,000           \$21,000,000         \$100,000         \$100,000         \$100,000           \$21,000,000         \$100,000         \$100,000         \$100,000           \$21,000,000         \$100,000         \$100,000         \$100,000           \$20,000         \$20,000         \$20,000         \$20,   | (\$100,000)<br>(\$150,000)<br>(\$100,000)   | (\$1,084,329)<br>(\$37,283)<br>(\$188,674)<br>(\$75,000)  | \$100,000<br>\$915,671<br>\$500,000<br>\$12,717<br>\$200,000<br>\$211,326<br>\$34,680<br>\$0<br>\$75,000<br>\$0   |
| \$1,000,000         \$1,000,000           Greeign Regi         \$500,000         \$0         \$500,000           sord,000         \$0         \$500,000         \$0           sordium on t         \$250,000         \$0         \$200,000           sordium on t         \$250,000         \$0         \$200,000           sordium on t         \$250,000         \$0         \$500,000           sordium on t         \$250,000         \$150,000         \$400,000           \$0         \$75,000         \$75,000         \$74,600           \$0         \$150,000         \$100,000         \$100,000           \$0         \$100,000         \$100,000         \$100,000           \$0         \$100,000         \$10,000         \$100,000           \$1,000,000         \$150,000         \$1,500,000         \$1,500,000           \$2,100,000         \$150,000         \$1,500,000         \$1,500,000           \$2,100,000         \$150,000         \$1,500,000         \$1,500,000           \$2,000         \$2,500         \$2,500         \$2,500           \$2,000         \$2,500         \$2,500         \$2,500           \$2,000         \$2,500         \$2,500         \$2,500           \$2,000         \$2,500   | (\$100,000)<br>(\$150,000)<br>(\$100,000)   | (\$1,084,329)<br>(\$37,283)<br>(\$188,674)<br>(\$75,000)  | \$915,671<br>\$500,000<br>\$12,717<br>\$220,000<br>\$211,326<br>\$34,680<br>\$0<br>\$75,000<br>\$0  |
| oreign Regi         \$500,000         \$0         \$500,000           sortium on t         \$200,000         \$150,000         \$50,000           sortium on t         \$2500,000         \$150,000         \$400,000           sortium on t         \$2500,000         \$150,000         \$400,000           sortium on t         \$2500,000         \$150,000         \$24,680           bonors         \$0         \$150,000         \$150,000           \$0         \$150,000         \$150,000         \$150,000           \$0         \$150,000         \$11,50,000         \$11,50,000           \$0         \$150,000         \$11,50,000         \$11,50,000           \$0         \$150,000         \$11,50,000         \$11,50,000           \$0         \$100,000         \$11,00,000         \$11,00,000           \$1,000,000         \$11,00,000         \$11,00,000         \$12,00,000           \$21,000,000         \$11,00,000         \$12,00,000         \$12,00,000           \$21,000,000         \$100,000         \$12,00,000         \$12,00,000           \$220,000         \$220,000         \$220,000         \$220,000           \$20,000         \$0         \$20,000         \$20,000           \$20,000         \$20,000 <t< td=""><td>(\$100,000)<br/>(\$150,000)<br/>(\$150,000)</td><td>(\$188,674)</td><td>\$500,000<br/>\$12,717<br/>\$200,000<br/>\$211,326<br/>\$34,680<br/>\$0<br/>\$75,000<br/>\$0</td></t<>   | (\$100,000)<br>(\$150,000)<br>(\$150,000)   | (\$188,674)   | \$500,000<br>\$12,717<br>\$200,000<br>\$211,326<br>\$34,680<br>\$0<br>\$75,000<br>\$0   |
| \$50,000         \$0         \$50,000           sorrium on t         \$250,000         \$40,000           sorrium on t         \$250,000         \$40,000           sorrium on t         \$250,000         \$40,000           \$0         \$75,000         \$75,000           \$0         \$75,000         \$75,000           \$0         \$100,000         \$100,000           \$0         \$150,000         \$100,000           \$0         \$150,000         \$100,000           \$0         \$100,000         \$100,000           \$1,000,000         \$100,000         \$100,000           \$2,000         \$1,000,000         \$1,000,000           \$2,100,000         \$2,100,000         \$1,000,000           \$2,100,000         \$1,000,000         \$1,000,000           \$2,100,000         \$1,000,000         \$1,000,000           \$2,000         \$1,000,000         \$1,000,000           \$2,000         \$1,000,000         \$1,000,000           \$2,000         \$2,000         \$1,000,000           \$2,000         \$2,000         \$2,000           \$2,000         \$2,000         \$2,000           \$2,000         \$2,000         \$2,000           \$2,000   | (\$100,000)<br>(\$150,000)<br>(\$100,000)   | (\$188,674)   | \$12,717<br>\$200,000<br>\$211,326<br>\$34,680<br>\$0<br>\$75,000<br>\$0  |
| sortium on t         \$200,000         \$0         \$200,000           sortium on t         \$250,000         \$150,000         \$400,000           bonors         \$0         \$150,000         \$134,680           so         \$75,000         \$775,000         \$134,680           so         \$75,000         \$100,000         \$134,680           so         \$100,000         \$100,000         \$100,000           so         \$150,000         \$100,000         \$100,000           \$250,000         \$100,000         \$100,000         \$100,000           \$250,000         \$100,000         \$100,000         \$100,000           \$250,000         \$100,000         \$100,000         \$100,000           \$250,000         \$100,000         \$100,000         \$100,000           \$250,000         \$100,000         \$100,000         \$100,000           \$20,000         \$100,000         \$100,000         \$100,000           \$20,000         \$20,000         \$100,000         \$20,000           \$20,000         \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000         \$20,000  | (\$100,000)<br>(\$150,000)<br>(\$100,000)   | (\$188,674)   | \$200,000<br>\$211,326<br>\$34,680<br>\$0<br>\$75,000<br>\$0  |
| sortium on t         \$250,000         \$150,000         \$400,000         \$24,680           bonors         \$0         \$150,000         \$154,680         \$24,680           bonors         \$0         \$150,000         \$100,000         \$14,680           \$0         \$150,000         \$100,000         \$100,000           \$0         \$150,000         \$100,000         \$100,000           \$0         \$150,000         \$100,000         \$100,000           \$250,000         \$100,000         \$1,000,000         \$1,000,000           \$21,000,000         \$23,00         \$1,000,000         \$1,000,000           \$21,000,000         \$1,000,000         \$1,000,000         \$1,000,000           \$21,000,000         \$23,00         \$1,000,000         \$1,000,000           \$21,000,000         \$1,000,000         \$1,000,000         \$1,000,000           \$220,000         \$1,000,000         \$1,000,000         \$1,000,000           \$20,000         \$1,000,000         \$250,000         \$1,000,000           \$20,000         \$1,000,000         \$1,000,000         \$1,000,000           \$20,000         \$20,000         \$250,000         \$1,000,000           \$20,000         \$20,000         \$20,000         \$20,000   | (\$100,000)<br>(\$150,000)<br>(\$100,000)   | (\$18,674)  | \$211,326<br>\$34,680<br>\$0<br>\$75,000<br>\$0   |
| Sources         \$0         \$34,680           Donors         \$0         \$75,000         \$74,680           Son         \$75,000         \$75,000         \$74,680           \$0         \$150,000         \$100,000         \$100,000           \$0         \$150,000         \$100,000         \$100,000           \$0         \$150,000         \$100,000         \$100,000           \$0         \$175,000         \$11,000,000         \$100,000           \$1         \$25,100,000         \$11,000,000         \$11,000,000           \$21,100,000         \$25,100,000         \$11,000,000         \$12,000,000           \$21,100,000         \$21,000,000         \$11,000,000         \$12,000,000           \$21,000,000         \$21,000,000         \$11,000,000         \$226,000           \$22,100,000         \$11,000,000         \$226,000         \$12,000,000           \$22,100,000         \$10,000,000         \$226,000         \$12,000,000           \$20,000         \$226,000         \$120,000         \$226,000           \$20,000         \$226,000         \$226,000         \$226,000           \$20,000         \$226,000         \$226,000         \$226,000           \$20,000         \$226,000         \$226,000   | (\$100,000)<br>(\$150,000)<br>(\$100,000)   | (\$75,000)  | \$34,680<br>\$0<br>\$75,000<br>\$0  |
| bonors         \$0         \$75,000         \$75,000           \$0         \$150,000         \$15,000           \$0         \$100,000         \$150,000           \$0         \$100,000         \$150,000           \$0         \$150,000         \$150,000           \$0         \$150,000         \$100,000           \$0         \$150,000         \$11,000,000           \$1000,000         \$100,000         \$11,000,000           \$21,000,000         \$21,000,000         \$11,000,000           \$21,000,000         \$21,000,000         \$1260,000           \$220,000         \$103,000         \$253,000           \$20,000         \$103,000         \$250,000           \$20,000         \$250,000         \$250,000           \$20,000         \$250,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$0         \$20,000           \$20,000         \$0         \$20,000           \$0         \$20,000         \$20,000           \$0         \$20,000         \$20,000           \$0         \$20,000         \$20,000           \$0         \$20,000         \$20,000   |   | (\$75,000)  | \$75,000  |
| \$0         \$75,000         \$75,000           \$0         \$100,000         \$100,000           \$0         \$100,000         \$100,000           \$0         \$150,000         \$100,000           \$0         \$150,000         \$100,000           \$250,000         \$575,000         \$1,000,000           \$21,000,000         \$575,000         \$1,000,000           \$21,000,000         \$21,000,000         \$1,000,000           \$21,000,000         \$21,000,000         \$1,500,000           \$20,000         \$100,000         \$1,500,000           \$20,000         \$100,000         \$25,000           \$20,000         \$25,000         \$20,000           \$20,000         \$25,000         \$20,000           \$20,000         \$25,000         \$20,000           \$20,000         \$25,000         \$20,000           \$20,000         \$25,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$   |   |   | \$75,000  |
| \$0         \$100,000         \$100,000           \$0         \$150,000         \$100,000           \$0         \$150,000         \$100,000           \$0         \$150,000         \$100,000           \$0         \$75,000         \$10,150,000           \$25,750,000         \$10,150,000         \$1,000,000           \$21,000,000         \$750,000         \$1,500,000           \$21,000,000         \$21,000,000         \$1,500,000           \$20,000         \$100,000         \$253,000           \$20,000         \$100,000         \$250,000           \$20,000         \$100,000         \$250,000           \$20,000         \$25,000         \$20,000           \$20,000         \$25,000         \$25,000           \$20,000         \$25,000         \$25,000           \$20,000         \$25,000         \$20,000           \$20,000         \$25,000         \$20,000           \$20,000         \$25,000         \$20,000           \$20,000         \$25,000         \$20,000           \$20,000         \$25,000         \$25,000           \$20,000         \$25,000         \$25,000           \$20,000         \$250,000         \$25,000           \$20,000   |   |   | 8 8   |
| \$0         \$150,000         \$150,000           \$0         \$100,000         \$100,000           \$4 400,000         \$5,750,000         \$1,000,000           \$250,000         \$1,000,000         \$1,000,000           \$2,100,000         \$2,300,000         \$1,500,000           \$4,400,000         \$25,300,000         \$1,500,000           \$2,100,000         \$25,300,000         \$25,000           \$4,00,000         \$160,000         \$25,000           \$20,000         \$10,500,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000           \$20,000         \$20,000         \$20,000  |   |   | Ş   |
| \$0 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$100,000 \$1,000 \$1,000 \$1,000 \$1,000 \$1,000 \$1,000 \$1,000 \$1,000 \$1,000 \$1,000 \$1,000 \$1,000 \$1,000   |   |   | 3   |
| \$0 \$75,000 \$10 \$275,000 \$10 \$25,000 \$10 \$25,000 \$10 \$25,000 \$10 \$25,000 \$10 \$25,000 \$10 \$25,000 \$10 \$25,000 \$2   | (\$75,000)<br>\$1,275,000<br>(\$700,000)  |   | \$0   |
| ## 1750,000 \$10  \$250,000 \$1750,000 \$110  \$1,000,000 \$2,300,000 \$1  \$1,000,000 \$2,300,000 \$1  \$1,000,000 \$1,300 \$1  \$1,000,000 \$1,300 \$1  \$2,300,000 \$1,300 \$1  \$2,000,000 \$1,000,000 \$1  **Afo,000 \$1,000 \$1  \$30,000 \$2,300,000 \$1  **Afo,000 \$1,300 \$1  **Afo,000 \$1  **A  | \$1,275,000<br>(\$700,000)  |   | 20  |
| \$250,000   \$750,000   \$1   | (\$700.000)   |   | \$11,425,000  |
| \$1,000,000   \$500,000   \$1,000,000   \$2,300,000   \$4,20  |   | (\$232,167)   | \$67,833  |
| S2,100,000   \$2,300,000   \$4   S450,000   \$103,000   \$1   Center Co   \$100,000   \$160,000   \$1   \$400,000   \$650,000   \$1   \$20,000   \$30   \$30,000   \$25,000   \$20,000   \$1   \$200,000   \$20,000   \$0   \$20,000   \$20,000   \$0   \$20,000   \$20,000   \$0   \$20,000   \$20   | (\$1,200,000)   |   | \$300,000   |
| r 550,000 \$103,000 \$103,000 \$1 Center Co \$100,000 \$160,000 \$1 Go,000 \$1 Go,0  | \$547,141 \$1,303,265   |   | \$6,250,406   |
| r Center Co \$100,000 \$160,000 \$1  r \$400,000 \$500,000 \$1  r \$30,000 \$30  \$30,000 \$25,000  \$20,000 \$25,000  \$100,000 \$25,000  ampaigns \$550,000 \$0  \$0 \$0000  \$0 \$0000  \$0 \$0000  \$0 \$000  \$0 \$000  \$0 \$0000  \$0 \$0000  \$0 \$0000  \$0 \$0000  \$0 | (\$547,141)   |   | \$5,859   |
| r \$500,000 \$650,000 \$1  \$20,000 \$0  \$30,000 \$20,000  \$30,000 \$250,000  \$20,000 \$0  \$0  ampaigns \$550,000 \$0  \$0  \$0  \$0  \$0  \$0  \$0  \$0  \$0   | (\$125,000)   |   | \$135,000   |
| r \$20,000 \$0  \$30,000 \$20  \$30,000 \$25,000  \$20,000 \$0  Activities \$150,000 \$0  ampaigns \$550,000 \$0  \$0 \$0   |   | (\$77,709)  | \$972,291   |
| \$39,000 \$0 \$39,000 \$25,000 \$20,000 \$0 Activities \$150,000 \$0 \$0 ampaigns \$550,000 \$0 \$0 \$0   | (\$20,000)  |   | \$0   |
| \$30,000 \$25,000 \$20,000 \$0 Activities \$150,000 \$0 \$0 ampaigns \$550,000 \$0 \$   |   | (\$26,102)  | \$3,898   |
| \$20,000         \$0           Activities         \$150,000         \$0         \$           ampaigns         \$550,000         \$0         \$  |   | (\$38,642)  | \$16,358  |
| Activities         \$150,000         \$0           ampaigns         \$550,000         \$0           en         \$60,000         \$0   | (\$20,000)  |   | 0\$   |
| ampaigns \$550,000 \$0  | \$372,000   | (\$42,401)  | \$479,599   |
| 0.0 053   |   | (\$146)   | \$549,854   |
| 200,000   |   | (\$50,000)  | \$0   |
| 36 Long Term Blood Storage Alternative Investigations 50 \$96,375   | \$96,375 (89,000)   | 250,000   | \$256,989   |
| \$300,000 \$337,000   |   | \$ (21,703)   | \$615,297   |
| cts Software  | \$350,000 (\$83,201)  |   | \$266,799   |
| \$24,600,000 \$21,000,000 \$45,600,000 \$0 \$0  |   | 0\$ 0\$   | \$0 \$45,600,000  |

2/3/97 11:25 AM \* Date is the date of ONR Contracting Officer Written Approval to the NMDP



# NMDP DNA PROJECT

#### **DONOR TYPINGS PERFORMED**

# December 1, 1996 - December 31, 1996

| TOTAL      | 15,829 |  |
|------------|--------|--|
| PRIORITY 3 | 895    |  |
| PRIORITY 2 | 12,100 |  |
| PRIORITY 1 | 2,834  |  |
|            |        |  |

# NMDP DNA PROJECT

#### DONOR SAMPLES STORED

#### December 1, 1996 - December 31, 1996

| ARC - NATIONAL | 23,646 |  |
|----------------|--------|--|
| PITTSBURGH     | 7,871  |  |
| mora v         |        |  |
| TOTAL          | 31,517 |  |

#### **DONOR SAMPLES SHIPPED**

#### December 1, 1996 - December 31, 1996

| ARC - NATIONAL | 6,977  |  |
|----------------|--------|--|
| PITTSBURGH     | 8,200  |  |
| TOTAL          | 15,177 |  |

1996 ASH SYMPOSIUM REGISTRATION SUMMARY

# 1996 ASH SYMPOSIUM REGISTRATION SUMMARY

|             |       |      | SPE  | CIAL | TIES   |       | PHYSICIAN TYPE |          |            | DEGREE |      |       |      |       |
|-------------|-------|------|------|------|--------|-------|----------------|----------|------------|--------|------|-------|------|-------|
|             | Total | Hem. | Onc. | Ped. | Trans. | Other | Resident       | Academic | Practicing | Other  | M.D. | Ph.D. | D.O. | Other |
| Domestic    | 169   | 71   | 52   | 35   | 52     | 16    | 26             | 56       | 13         | 36     | 98   | 25    | 1    | 24    |
| Unknown     | 5     |      |      |      |        |       |                |          |            |        |      |       |      |       |
| Argentina   | 2     | 1    |      | 1    |        |       |                |          | 1          |        |      |       |      |       |
| Australia   | 1     |      | 1    | 1    | 1      |       |                |          |            |        |      |       |      |       |
| Austria     | 1     |      |      |      |        |       |                |          |            |        |      |       |      |       |
| Belgium     | 4     | 4    | 1    |      |        |       |                | 3        | 1          |        | 4    | 2     |      |       |
| Brazil      | 1     |      |      |      | 1      |       |                | 1        |            |        | 1    |       |      |       |
| Canada      | 13    | 4    | 1    | 4    | 3      | 3     |                | 6        | 1          | 3      | 6    | 4     |      | 1     |
| Chile       | 2     | 1    | 1    |      |        |       |                | 1        |            |        | 1    |       |      |       |
| Egypt       | 1     | 1    |      |      | 1      |       |                | 1        | 1          |        | 1    |       |      |       |
| England     | 2     |      |      |      |        |       |                |          |            |        |      |       |      |       |
| Finland     | 3     | 1    |      | 1    |        |       | 1              |          | 1          |        | 2    |       |      | ٠.    |
| France      | 6     | 5    |      |      |        |       |                |          | 4          | 1      | 4    |       |      | 1     |
| Germany     | 9     | 7    | 3    | 2    | 4      |       | 3              | 3        | 1          | 1      | 8    | 2     |      |       |
| reece       | 1     |      |      |      |        |       |                |          |            |        |      |       |      |       |
| Ireland     | 1     | 1    | 1    | 1    |        |       |                |          | 1          |        | 1    |       |      |       |
| Israel      | 2     | 1    | 1    |      |        |       |                | 1        |            |        | 1    |       |      |       |
| Italy       | 13    | 6    |      | 5    | 2      |       | 2              | 1        | 7          |        | 10   | 1     | 1    |       |
| Korea       | 2     |      |      | 1    |        |       |                |          | 1          |        | 1    | 1     |      |       |
| Mexico      | 3     | 2    |      | 1    |        |       |                |          | 2          |        | 2    |       |      |       |
| Netherlands | 1     |      |      |      |        |       |                |          |            |        |      |       |      |       |
| Norway      | 2     | 2    |      |      |        |       |                | 2        |            |        | 1    | 1     |      |       |
| Peru        | 1     | 1    |      |      |        |       |                | 1        | 1          |        | 2    |       |      |       |
| Poland      | 2     | 1    |      |      | 1      |       |                | 1        |            |        | 1    | 1     |      |       |
| Singapore   | 1     | 1    | 1    | 1    |        |       |                | 1        |            |        | 1    |       |      |       |
| Spain       | 6     | 6    |      |      | 1      |       |                | 5        |            |        | 5    | 1     |      |       |
| Sweden      | 6     | 4    | 1    | 3    |        |       |                | 4        | 1          |        | 5    | 3     |      |       |
| Switzerland | 1     | 1    |      |      |        |       |                | 1        |            |        | 1    | 1     |      | ٠.    |
| Taiwan      | 2     | 2    |      |      |        |       |                |          | 2          |        | 2    |       |      |       |
| ŲK          | 2     | 1    |      | 1    |        | 1     |                |          | 2          |        | 2    |       |      |       |
| ruguay      | 1     | 1    | 1    | 1    |        |       |                |          |            |        | 1    |       |      |       |
| TOTAL       | 266   | 125  | 64   | 58   | 66     | 20    | 32             | 88       | 40         | 41     | 161  | 42    | 2    | 26    |

# ASH SYMPOSIUM EVALUATION

# EVALUATION Donor Option and Stem Cell Choices

Presented by the National Marrow Donor Program at the ASH Symposium in Orlando, FL

#### Friday, December 6, 1996

Evaluation Scale: 1 = poor 2 = fair 3 = average 4 = good 5 = excellent

| Evaluation Scale: $I = poor$   |                        | = good 3 = excellent      |
|--------------------------------|------------------------|---------------------------|
| Speaker/Topic                  | Clarify of Information | Usefulness of Information |
| The Role of Minor              | 0 = Poor               | 1 = Poor                  |
| Histocompatibility Antigens    | 1 = Fair               | 2 = Fair                  |
| Peter Parham, Ph.D.            | 5 = Average            | 4 = Average               |
|                                | 6 = Good               | 6 = Good                  |
|                                | 3 = Excellent          | 2 = Excellent             |
|                                | 1 = n/a                | 1 = n/a                   |
| New Methods to Overcome        | 0 = Poor               | 0 = Poor                  |
| HLA Disparity                  | 0 = Fair               | 1 = Fair                  |
| Paul Martin, M.D.              | 4 = Average            | 4 = Average               |
|                                | 6 = Good               | 7 = Good                  |
|                                | 5 = Excellent          | 3 = Excellent             |
|                                | 1 = n/a                | 1= n/a                    |
| Results of Mismatched Related  | 0 = Poor               | 0 = Poor                  |
| BMT                            | 2 = Fair               | 1 = Fair                  |
| Jean Henslee-Downey, M.D.      | 0 = Average            | 1 = Average               |
|                                | 12 = Good              | 10 = Good                 |
|                                | 3 = Excellent          | 5 = Excellent             |
|                                | 0 = n/a                | 0 = n/a                   |
| Clinical Outcome after Matched | 0 = Poor               | 0 = Poor                  |
| Unrelated Donor BMT            | 0 = Fair               | 1 = Fair                  |
| Claudio Anasetti, M.D.         | 0 = Average            | 0 = Average               |
|                                | 7 = Good               | 7 = Good                  |
|                                | 9 = Excellent          | 8 = Excellent             |
|                                | 0 = n/a                | 0 = n/a                   |
| Development in Cord Blood      | 0 = Poor               | 0 = Poor                  |
| Transplantation                | 1 = Fair               | 0 = Fair                  |
| Joanne Kurtzberg, M.D.         | 0 = Average            | 1 = Average               |
|                                | 6 = Good               | 6 = Good                  |
|                                | 9 = Excellent          | 9 = Excellent             |
| 1                              | 0 = n/a                | 0 = n/a                   |
| Transplants for CML            | 0 = Poor               | 0 = Poor                  |
| Philip McGlave, M.D.           | 0 = Fair               | 1 = Fair                  |
|                                | 1 = Average            | 1 = Average               |
| 1                              | 7 = Good               | 6 = Good                  |
|                                | 3 = Excellent          | 3 = Excellent             |
|                                | l = n/a                | 1 = n/a                   |

Overall Symposium Rating: Poor = 0; Fair = 0; Average = 0; Good = 9; Excellent = 3

What topics concerning unrelated donor transplantation would you like to see addressed in the future:

1. Status and relevance of any test (including HTLP/CTLP, etc., etc., etc., etc., of or prediction of GVH/GVL-go beyond the fixation of MHC typing.

2. Infections after MUD; especially viral diseases

3. PBSC MUD (as data becomes available).

4. HLA and outcome data--more about cell dose ala Dr. Anasetti's 3.7 x 10<sup>7</sup>/k median